Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model

Journal of Virology

Volumn 85, Issue 7, 2011, Pages 3067-3076

  Khong, Wei Xin ^a   Foo, Damian G W ^a,d   Trasti, Scott L ^b   Tan, Eng Lee ^b,c   Alonso, Sylvie ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SINGAPORE POLYTECHNIC   (Singapore)

^d MINISTRY OF HEALTH   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DISEASE SEVERITY; ENTEROPATHY; ENTEROVIRUS 71; HAND FOOT AND MOUTH DISEASE; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; MORTALITY; MOUSE; MUSCLE DISEASE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN ATROPHY; SPLEEN DISEASE; SURVIVAL RATE; TISSUE INJURY; TREATMENT OUTCOME; VIRUS LOAD;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; HISTOCYTOCHEMISTRY; INTERLEUKIN-6; INTESTINES; MICE; MICE, INBRED BALB C; MUSCLES; SEVERITY OF ILLNESS INDEX; SPLEEN; SURVIVAL ANALYSIS; VIRAL LOAD;

ANIMALIA; HUMAN ENTEROVIRUS 71; MUS;

EID: 79952583787     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01779-10     Document Type: Article

References (56)

1. Abe, Y., A. Horiuchi, M. Miyake, and S. Kimura. 1994. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol. Rev. 139:5-19.
2. Adkins, B., C. Leclerc, and S. Marshall-Clarke. 2004. Neonatal adaptive immunity comes of age. Nat. Rev. 4:553-564.
3. Brockman, M. A., et al. 2009. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 114:346-356.
4. Chan, L. G., et al. 2000. Deaths of children during an outbreak of hand, foot and mouth disease in Sarawak, Malaysia, clinical and pathological characteristics of the disease. Clin. Infect. Dis. 31:678-683.
5. Chang, L. Y., C. Y. Huang, and T. Y. Lin. 1998. Fulminant neurogenic pulmonary oedema with hand, foot and mouth disease. Lancet 352:367-368.
6. Chang, L. Y., et al. 1999. Clinical features and risk factors of pulmonary oedema after enterovirus 71-related hand, foot and mouth disease. Lancet 354:1682-1686.
7. Chen, Y. C., et al. 2004. A murine oral enterovirus 71 infection model with central nervous system involvement. J. Gen. Virol. 85:69-77.
8. Couper, K. N., D. G. Blount, and E. M. Riley. 2008. IL-10: the master regulator of immunity to infection. J. Immunol. 180:5771-5777.
9. Foo, D. G. W., et al. 2007. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 9:1299-1306. (Pubitemid 47539204)
10. Gijbels, K., S. Brocke, J. S. Abrams, and L. Steinman. 1995. Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol. Med. 1:795-805.
11. Gilbert, G. L., et al. 1988. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr. Infect. Dis. J. 7:484-488.
12. Girndt, M., and H. Kohler. 2003. Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk. Nephrol. Dial. Transplant. 18:1976-1979.
13. Hashimoto, I., and A. Hagiwara. 1982. Pathogenicity of a poliomyelitis-like disease in monkeys infected orally with enterovirus 71: a model for human infection. Neuropathol. Appl. Neurobiol. 8:149-156.
14. Heremans, H., C. Dillen, W. Put, V. J. Damme, and A. Billiau. 1992. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin associated with paradoxically increased IL-6 levels. Eur. J. Immunol. 22:2395-2401.
15. Herrero, L. J., et al. 2003. Molecular epidemiology of enterovirus 71 in peninsular Malaysia, 1997-2000. Arch. Virol. 148:1369-1385.
16. Huang, C. C., et al. 1999. Neurological complications in children with enterovirus 71 infection. N. Engl. J. Med. 341:936-942.
17. Ishihara, K., and T. Hirano. 2002. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 13:357-368.
18. Kanda, T., et al. 1996. Modification of viral myocarditis in mice by interleukin-6. Circ. Res. 78:848-856.
19. Kishimoto, T. 2006. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res. Ther. 8:2-10.
20. Kopf, M., et al. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339-342. (Pubitemid 24104268)
21. Kosai, K., et al. 2008. Gabexate mesilate suppresses influenza pneumonia in mice through inhibition of cytokines. J. Int. Med. Res. 36:322-328.
22. Lambert, P. H., M. Liu, and C. A. Siegrist. 2005. Can. successful vaccines teach us how to induce efficient protective immune responses? Nat. Med. 211:S54-S62.
23. Levy, O. 2007. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat. Rev. 7:379-390.
24. Lin, T. Y., et al. 2002. Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. Acta Paediatr. 91:632-635.
25. Lin, T. Y., S. H. Hsia, Y. C. Huang, C. T. Wu, and L. Y. Chang. 2003. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin. Infect. Dis. 36:269-274.
26. Lin, Y. W., S. W. Wang, Y. Y. Tung, and S. H. Chen. 2009. Enterovirus 71 infection of human dendritic cells. Exp. Biol. Med. (Maywood) 234:1166-1173.
27. Liu, C. C., H. W. Tseng, S. M. Wang, J. R. Wang, and I. J. Su. 2000. An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J. Clin. Virol. 17:23-30.
28. Lum, L. C., et al. 1998. Fatal enterovirus 71 encephalomyelitis. J. Pediatr. 133:795-798. (Pubitemid 28563953)
29. Mangia, A., et al. 2004. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine 25:103-109. (Pubitemid 38096267)
30. Marby, D., G. R. Lockhart, R. Raymond, and J. G. Linakis. 2001. Antiinterleukin-6 antibodies attenuate inflammation in a rat meningitis model. Acad. Emerg. Med. 8:946-949.
31. McMinn, P. C., et al. 2001. Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia. J. Virol. 75:7732-7738.
32. Moore, K. W., D. W. Malefyt, R. R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765.
33. Nagata, N., et al. 2004. Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J. Gen. Virol. 85:2981-2989.
34. Naicker, D. D., et al. 2009. Interleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis. J. Infect. Dis. 200:448-452.
35. Nathanson, N. 2008. The pathogenesis of poliomyelitis: what we don't know. Adv. Virus Res. 71:1-50.
36. Ong, K. C., et al. 2008. Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J. Neuropathol. Exp. Neurol. 67:532-542.
37. Poffenberger, M. C., et al. 2009. Lack of IL-6 during Coxsackievirus Infection heightens the early immune response resulting in increased severity of chronic autoimmune myocarditis. PLoS One 4:e6207.
38. Program for Monitoring Emerging Diseases. 2001. Enterovirus 71. International Society for Infectious Diseases, Brookline, MA. http://www.promedmail.org.
39. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:4931-4937.
40. Sasaki, O., T. Karaki, and J. Imanishi. 1986. Protective effect of interferon on infections with hand, foot, and mouth disease virus in newborn mice. J. Infect. Dis. 153:498-502.
41. Schmidt, N. J., E. H. Lennette, and H. H. Ho. 1974. An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 129:304-309.
42. Siegrist, C. A. 2001. Neonatal and early life vaccinology. Vaccine 19:3331-3346.
43. Singh, S., C. L. Poh, and V. T. Chow. 2002. Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore (2000). Microbiol. Immunol. 46:801-808.
44. Starnes, H. F. J., et al. 1990. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-challenge in mice. J. Immunol. 145:4185-4191.
45. Tan, E. L., et al. 2006. Specific detection of enterovirus 71 directly from clinical specimens using real-time RT-PCR hybridization probe assay. Mol. Cell Probes 20:135-140. (Pubitemid 43343727)
46. Tan, E. L., T. M. C. Tan, V. T. K. Chow, and C. L. Poh. 2007. Inhibition of enterovirus 71 in virus-infected mice by RNA interference. Mol. Ther. 15:1931-1938.
47. Tanaka, T., et al. 2001. Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-alpha. J. Mol. Cell Cardiol. 33:1627-1635.
48. van Zaanen, H. C., et al. 1996. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL-6 antibodies indicates the existence of a positive feed-back loop. J. Clin. Invest. 98:1441-1448.
49. Wang, S. M., T. Ho, C. Shen, and C. C. Liu. 2008. Enterovirus 71, one virus and many stories. Pediatr. Neonatol. 49:113-115.
50. Wang, S. M., et al. 2006. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J. Clin. Virol. 37:47-52.
51. Wang, S. M., et al. 2003. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J. Infect. Dis. 188:564-570.
52. Wang, S. M., et al. 2007. Cerebrospinal fluid and cytokines in enterovirus 71 brain stem encephalitis and echovirus meningitis infections of varying severity. Clin. Microbiol. Infect. 13:677-682.
53. Wang, Y., et al. 2004. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J. Virol. 78:7916-7924. (Pubitemid 38944277)
54. Weng, K. F., L. L. Chen, P. N. Huang, and S. R. Shih. 2010. Neural pathogenesis of enterovirus 71 infection. Microbes Infect. 12:505-510.
55. World Health Organization. 2009. Hand, foot and mouth disease: a rising menace in Asia. World Health Organization for the Western Pacific, Manila, Philippines. http://www.wpro.who.int/media-centre/news/news-20090713.htm.
56. Yan, J. J., J. R. Wang, C. C. Liu, H. B. Yang, and I. J. Su. 2000. An outbreak of enterovirus 71 in Taiwan 1998-a comprehensive pathological, virological and molecular study on a case of fulminant encephalitis. J. Clin. Virol. 17:13-22.